11/28/2021 | Press release | Distributed by Public on 11/28/2021 06:13
Chicago - November 28, 2021 - At the Radiological Society of North America's (RSNA) 2021 Annual Meeting, GE Healthcare unveiled around 60 innovative technology solutions spanning the healthcare spectrum including patient screening, diagnostics, therapy planning, guidance, and monitoring. Amidst a global pandemic and mounting pressure on the industry, the company accelerated innovations underpinned by artificial intelligence (AI) and digital solutions to help transform healthcare delivery, making it easier and more efficient for clinicians and health systems, and more personalized and precise for patients.
The pandemic exposed the fragility of the global healthcare system, creating an urgent need for technology and solutions that help clinicians manage seriously ill COVID-19 patients, advanced diseases - such as cancer and heart disease - a backlog in non-urgent care, and an ageing population, while battling burnout and workforce shortages.
With these circumstances in mind, GE Healthcare is proud to introduce technologies and solutions at #RSNA21 that help healthcare systems:
"Our goal is to make healthcare more human by breaking down barriers so clinicians can work at the top of their game, healthcare systems can operate more efficiently, and patients can get the best and most personalized care possible," said Kieran Murphy, president & CEO, GE Healthcare. "Healthcare is at a turning point and at GE Healthcare we are using our clinical expertise and know-how to deliver innovative technologies and solutions that help solve healthcare's most pressing problems, advance precision health and improve patient lives."
Transforming healthcare through imaging technologies and digital offerings
Over the last year and a half, the industry has embraced technological innovation. What was once considered "futuristic" is now fundamental. In an environment where clinical expertise, regulatory know-how and speed matter, GE Healthcare rose to the challenge. Working alongside clinicians and care teams to understand the most pressing needs of radiologists and hospital administrators, the company innovated new solutions, leveraging its healthcare-specific intelligence platform, Edison, to help providers achieve greater efficiency, reduce errors, increase speed to appropriate treatments, and increase access to care.
To this end, GE Healthcare developed the following new AI-powered, automated and data-driven solutions to help encourage greater diagnostic confidence, ease the burden of care and improve workflow for healthcare systems around the world:
A partner of choice creating and investing in new possibilities for the healthcare industry
As innovators, integrators and clinical experts, GE Healthcare is aligning its products and solutions across care pathways, such as oncology, to create end-to-end solutions.
The company is working with industry leaders, such as SOPHiA GENETICS, to deliver on the promise of integrated cancer care by bringing insights across multiple diagnostic modalitieswith the goal of better targeting and matching treatments to each patient's cancer type, helping to ensure more effective and personalized treatment. Through the acquisition of Zionexa, the company is advancing precision diagnostics and impacting clinical care by commercializing innovative molecular imaging agents.
Furthermore, GE Healthcare offers deep industry expertise, an ability to merge clinical and data science and a breadth of solutions across pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, nuclear medicine, advanced digital solutions, and pharmaceutical partnerships - all to help clinicians enhance patient care from discovery to diagnosis to treatment.
Using input from clinical partners, GE Healthcare has designed technologies and digital solutions to keep up with the ever-changing challenges that exist in the imaging world. The Revolution Apex platform, for example, is designed with advanced technologies intended to:
"I'm a fan of the new Apex [platform] system and all the possibilities around it. For us, it's a big win," said Johan de Mey, MD, PhD, Chair of Radiology at the Universitair Ziekenhuis, Brussels, Belgium. "In the past, we kept machines as long as possible, and we upgraded them with software. But if the hardware was obsolete, we removed it from the hospital. With the Apex, we have a platform with the latest technology and can easily upgrade as our clinical practice evolves."
Altogether, GE Healthcare is a partner of choice to thousands of healthcare providers, medical technology innovators, and digital start-ups around the world.
About GE Healthcare:
GE Healthcare is the $17 billion* healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. On November 9, 2021, GE announced plans to spin-off GE Healthcare to create a pure-play company at the center of precision health in early 2023.
[i] SIGNA™ Hero is 510(k) pending at FDA. Not yet CE marked. Not available for sale in the United States or the EU. Not commercially available in all markets.
[ii] AIR Recon DL 3D and PROPELLER is 510(k) pending at the FDA. Not CE marked. Not available for sale in the United States or EU. Not commercially available in all markets.
[iii] SIGNA Artist Evo is 510(k) pending with the US FDA. Not yet CE Marketed. Not available for sale in the United States or EU. Not commercially available in all markets.
[iv] GE Healthcare's Revolution Apex platform is FDA 510(k) cleared and not available for sale in all countries.
[v] AutoRight refers to intelligent image chain features of GEHC's Interventional x-ray systems, from image acquisition to image processing and display.
[vi] Liver ASSIST Virtual Parenchyma is 510(k) cleared at FDA and CE Marked. Not available for sale in all countries.
[vii] Liver ASSIST Virtual Parenchyma solution includes Hepatic VCAR and FlightPlan for Liver with Parenchyma Analysis option and requires AW workstation with Volume Viewer, Volume Viewer Innova, Vision 2, VesselIQ Xpress, Autobone Xpress. These applications are sold separately. FlightPlan for Liver with Parenchyma Analysis option may not be available for sale in all countries.
[viii] GE Data on File. The lift force reduction is based upon the average lift force for the AMX Navigate of 11.0 N as compared to the Optima XR240amx average lift force of 58.3 N.
[ix] Anywhere the Internet is available.
[x] Cloud deployment currently only available in USA.
[xi] Scalability and upgradability are subject to the availability and compatibility of new capabilities and products.
[xii] 0.23sec and 19.5msec are 510k pending and not available for sales in all countries. 19.5msec effective temporal resolution is achieved by a 6x improvement of motion-blur reduction while maintaining high spatial resolution as demonstrated in cardiac phantom testing. The reduction in motion artifacts is comparable to a 0.039 equivalent gantry rotation speed with effective temporal resolution of 19.5 msec, as demonstrated in mechanical and mathematical phantom testing.